REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies today announced four preclinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA.
Poster Presentations:
Abstract Title: Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of γδ T Cell Immunotherapy
Poster/Abstract Number: 198
Presenting Author: Marissa Herrman, Ph.D.
Date/Time: November 11, 2022 from 9:00am – 9:00pm EST
Title: Preclinical Discovery and Characterization of Allogeneic anti-PSMA γδ CAR T Therapy for Prostate Cancer
Poster/Abstract Number: 203
Presenting Author: Nitya S. Ramadoss, Ph.D.
Date/Time: November 10, 2022 from 9:00am – 9:00pm EST
Abstract Title: Allogeneic “off-the-shelf” γδ T cells modified with CD27- containing CAR for targeting CD70+ cancers
Poster/Abstract Number: 246
Presenting Author: Kevin P. Nishimoto, Ph.D.
Date/Time: November 11, 2022 from 9:00am – 9:00pm EST
Abstract Title: Preclinical Discovery and Evaluation of Allogeneic “off-the-shelf” γδ CAR T Cells Targeting B7-H6+ Tumors
Poster/Abstract Number: 247
Presenting Author: Kevin P. Nishimoto, Ph.D.
Date/Time: November 10, 2022 from 9:00am – 9:00pm EST
The abstracts will be available in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on Monday, November 7 at 8:00am EST on www.sitcancer.org.
R&D Webcast
Adicet will host an R&D webcast presentation on Thursday, November 10, 2022 at 9:00am EST to provide an overview of its R&D pipeline.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies engineered to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.
